These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11354277)

  • 21. Virological and clinical implication of core promoter C1752/V1753 and T1764/G1766 mutations in hepatitis B virus genotype D infection in Mongolia.
    Elkady A; Tanaka Y; Kurbanov F; Oynsuren T; Mizokami M
    J Gastroenterol Hepatol; 2008 Mar; 23(3):474-81. PubMed ID: 18318825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations in pre-core and basic core promoter regions of hepatitis B virus in chronic hepatitis B patients.
    Wang XL; Ren JP; Wang XQ; Wang XH; Yang SF; Xiong Y
    World J Gastroenterol; 2016 Mar; 22(11):3268-74. PubMed ID: 27004005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis B virus (HBV) genotypes/subgenotypes in China: mutations in core promoter and precore/core and their clinical implications.
    Yuan J; Zhou B; Tanaka Y; Kurbanov F; Orito E; Gong Z; Xu L; Lu J; Jiang X; Lai W; Mizokami M
    J Clin Virol; 2007 Jun; 39(2):87-93. PubMed ID: 17451999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations of pre-core and basal core promoter before and after hepatitis B e antigen seroconversion.
    Kamijo N; Matsumoto A; Umemura T; Shibata S; Ichikawa Y; Kimura T; Komatsu M; Tanaka E
    World J Gastroenterol; 2015 Jan; 21(2):541-8. PubMed ID: 25593470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of hepatitis B virus X and core promoter mutations on hepatocellular carcinoma among patients infected with subgenotype C2.
    Shinkai N; Tanaka Y; Ito K; Mukaide M; Hasegawa I; Asahina Y; Izumi N; Yatsuhashi H; Orito E; Joh T; Mizokami M
    J Clin Microbiol; 2007 Oct; 45(10):3191-7. PubMed ID: 17652471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Study on the distribution of hepatitis B virus precore and basic core promoter mutations in Guizhou area].
    Ding JJ; Liu YH; Wang M
    Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Feb; 28(2):169-72. PubMed ID: 17649690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants.
    Parekh S; Zoulim F; Ahn SH; Tsai A; Li J; Kawai S; Khan N; Trépo C; Wands J; Tong S
    J Virol; 2003 Jun; 77(12):6601-12. PubMed ID: 12767980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations.
    Alexopoulou A; Theodorou M; Dourakis SP; Karayiannis P; Sagkana E; Papanikolopoulos K; Archimandritis AJ
    J Viral Hepat; 2006 Sep; 13(9):591-6. PubMed ID: 16907845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis B genotypes and the response to interferon therapy.
    Kao JH; Wu NH; Chen PJ; Lai MY; Chen DS
    J Hepatol; 2000 Dec; 33(6):998-1002. PubMed ID: 11131465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Relationship between core gene mutations of hepatitis B virus and response to alpha interferon therapy in chronic hepatitis B].
    Yoo BC; Kim HJ; Do JH; Park SM
    Taehan Kan Hakhoe Chi; 2002 Dec; 8(4):381-8. PubMed ID: 12506242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion.
    Chan HL; Hussain M; Lok AS
    Hepatology; 1999 Mar; 29(3):976-84. PubMed ID: 10051506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of response to treatment of chronic hepatitis B with pegylated interferon in the Philippines.
    Agdamag DM; Kageyama S; Leaño PS; Solante RM; Telan EF; Que ER; Ichimura H
    J Med Virol; 2010 Feb; 82(2):213-9. PubMed ID: 20029814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance.
    Hou J; Schilling R; Janssen HL; Hansen BE; Heijtink R; Sablon E; Williams R; Lau GK; Schalm SW; Naoumov NV
    J Med Virol; 2007 Aug; 79(8):1055-63. PubMed ID: 17596838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Core promoter mutations 3 years after anti-hepatitis B e seroconversion in patients with chronic hepatitis B or hepatitis B and C infection and cancer remission.
    Zampino R; Marrone A; Karayiannis P; Cirillo G; del Giudice EM; Rania G; Utili R; Ruggiero G
    Am J Gastroenterol; 2002 Sep; 97(9):2426-31. PubMed ID: 12358268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of core promoter/precore mutations and viral load in e antigen-negative chronic hepatitis B patients.
    Huang YH; Wu JC; Chang TT; Sheen IJ; Huo TI; Lee PC; Su CW; Lee SD
    J Viral Hepat; 2006 May; 13(5):336-42. PubMed ID: 16637865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of quantitative assays for hepatitis B e antigen and IgM antibody to hepatitis B core antigen to monitor therapy in chronic hepatitis B.
    Hayashi PH; Beames MP; Kuhns MC; Hoofnagle JH; Di Bisceglie AM
    Am J Gastroenterol; 1996 Nov; 91(11):2323-8. PubMed ID: 8931411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro resistance to interferon-alpha of hepatitis B virus with basic core promoter double mutation.
    Wang Y; Wei L; Jiang D; Cong X; Fei R; Chen H; Xiao J; Wang Y
    Antiviral Res; 2007 Aug; 75(2):139-45. PubMed ID: 17397939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis B virus precore/core variation and interferon therapy.
    Fattovich G; McIntyre G; Thursz M; Colman K; Giuliano G; Alberti A; Thomas HC; Carman WF
    Hepatology; 1995 Nov; 22(5):1355-62. PubMed ID: 7590647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Relationship between Shenzhen HBV genotype and precore/core promoter mutation and antiviral effects].
    Yuan J; Zhou BP; Gong ZJ; Xu LM; Jiang XL; Mizokami M
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Mar; 20(1):30-2. PubMed ID: 16642214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Specific mutations in the enhancer II/core promoter/precore regions of hepatitis B virus subgenotype C2 in Korean patients with hepatocellular carcinoma.
    Kim JK; Chang HY; Lee JM; Baatarkhuu O; Yoon YJ; Park JY; Kim DY; Han KH; Chon CY; Ahn SH
    J Med Virol; 2009 Jun; 81(6):1002-8. PubMed ID: 19382267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.